View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 1, 2020updated 09 Jun 2020 3:28pm

Encouraging interim results from ongoing Covid-19 clinical trials

By Victoria Smith

The number of Covid-19 cases and deaths is increasing daily across the US, and companies and researchers are working around-the-clock to discover a vaccine. Drug candidates are currently going the stages of clinical trial testing and investigators are making interim results available while trials are still taking place. The results from completed trials so far have offered mixed outcomes.

Immunosuppressive drug hydroxychloroquine was first approved for the treatment of malaria and is a current lupus treatment. However, it recently failed to meet endpoints, displaying adverse events in a retrospective study conducted at the United States Veterans Health Administration medical centres. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena